scholarly journals Efficacy and safety of hospital-based group medical quarantine for dialysis patients exposed to coronavirus disease 2019

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Li Zuo ◽  
Yu Xu ◽  
Xin-Ju Zhao ◽  
Wu-Dong Guo ◽  
Xiao-Dan Li ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Dialysis Patients

scholarly journals Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

2019 ◽  
Vol 23 (6) ◽  
pp. 739-748 ◽  
Author(s):  
Kazuhiko Tsuruya ◽  
◽  
Ryutaro Shimazaki ◽  
Masafumi Fukagawa ◽  
Tadao Akizawa
Keyword(s):  
Peritoneal Dialysis ◽  
Efficacy And Safety ◽  
Dialysis Patients

scholarly journals Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis

2016 ◽  
Vol 10 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Ryota Niikura ◽  
Takako Serizawa ◽  
Atsuo Yamada ◽  
Shuntaro Yoshida ◽  
Mariko Tanaka ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Efficacy And Safety ◽  
Tarry Stool ◽  
Dialysis Patients ◽  
Stromal Tumors ◽  
Duodenal Gist ◽  
Johnson Syndrome ◽  
Old Japanese ◽  
Steven Johnson Syndrome

The number of cancer patients undergoing dialysis has been increasing, and the number of these patients on chemotherapy is also increasing. Imatinib is an effective and safe therapy for KIT-positive gastrointestinal stromal tumors (GIST), but the efficacy and safety of imatinib in dialysis patients remain unclear. Because clinical trials have not been conducted in this population, more investigations are required. We report on a 75-year-old Japanese man undergoing dialysis who presented with massive tarry stool from a duodenal GIST. The duodenal GIST was 14 cm in diameter with multiple liver and bone metastases. The patient underwent an urgent pancreaticoduodenectomy to achieve hemostasis. After surgery, he was administered imatinib 400 mg/day. No severe adverse event including myelosuppression, congestive heart failure, liver functional impairment, intestinal pneumonia, or Steven-Johnson syndrome occurred, and the liver metastasis remained stable for 4 months. During chemotherapy, hemodialysis continued three times per week without adverse events. We suggest that regular-dose imatinib is an effective and safe treatment in patients with GIST undergoing dialysis. In addition, we present a literature review of the effectiveness and safety of imatinib treatment in dialysis patients.

scholarly journals Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

2019 ◽  
Vol 23 (9) ◽  
pp. 1173-1173
Author(s):  
Kazuhiko Tsuruya ◽  
◽  
Ryutaro Shimazaki ◽  
Masafumi Fukagawa ◽  
Tadao Akizawa
Keyword(s):  
Peritoneal Dialysis ◽  
Efficacy And Safety ◽  
Dialysis Patients

scholarly journals Efficacy and Safety of a Novel ?-Agonist for Managing Intractable Pruritus in Dialysis Patients

2012 ◽  
Vol 36 (2) ◽  
pp. 175-183 ◽  
Author(s):  
Hiroo Kumagai ◽  
Toshiya Ebata ◽  
Kenji Takamori ◽  
Katsumasa Miyasato ◽  
Taro Muramatsu ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Dialysis Patients

Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism

Nephrology ◽  
2013 ◽  
Vol 18 (3) ◽  
pp. 194-200 ◽  
Author(s):  
Loke Meng Ong ◽  
Punithavathi Narayanan ◽  
Heong Keong Goh ◽  
Anita Bhajan Manocha ◽  
Ahmad Ghazali ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Secondary Hyperparathyroidism ◽  
Controlled Trial ◽  
Efficacy And Safety ◽  
Dialysis Patients ◽  
Randomized Controlled

scholarly journals Bimodal Solutions or Twice-Daily Icodextrin to Enhance Ultrafiltration in Peritoneal Dialysis Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Periklis Dousdampanis ◽  
Konstantina Trigka ◽  
Joanne M. Bargman
Keyword(s):  
Peritoneal Dialysis ◽  
Clinical Effect ◽  
Fluid Management ◽  
Efficacy And Safety ◽  
Dialysis Patients

The efficacy and safety of icodextrin has been well established. In this paper, we will discuss the pharmacokinetics and biocompatibility of icodextrin and its clinical effect on fluid management in peritoneal dialysis patients. Novel strategies for its prescription for peritoneal dialysis patients with inadequate ultrafiltration are reviewed.

scholarly journals Efficacy and Safety of Melphalan 140mg/m2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5822-5822
Author(s):  
Hatem Ali ◽  
Baharani Jyoti ◽  
Shankaranarayana Paneesha ◽  
Richard Lovell ◽  
Alex George Kanellopoulos ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Renal Impairment ◽  
Stem Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Severe Renal Impairment ◽  
Efficacy And Safety ◽  
Dialysis Patients ◽  
Treatment Related Mortality ◽  
Related Mortality

Abstract Introduction: Information is currently available for the efficacy and safety of autologous stem cell transplantation (ASCT) conditioned with melphalan in multiple myeloma patients with mild to moderate chronic kidney disease. However, little information is available on ASCT in patients with severe renal impairment or those on dialysis with multiple myeloma. This population is usually not considered for ASCT due to a high risk of mortality. One retrospective study provides data on ASCT conditioned mainly with 200mg/m2 melphalan with high treatment related mortality (TRM) at 15%. Here we present safety and efficacy data on dose reduced melphalan (140/m2) conditioned ASCT in patients with severe renal impairment or haemodialysis at the time of transplant with a TRM of 0%. Patients and methods: We identified and report on 10 ASCT procedures carried out on 9 (7 males and 2 females) myeloma patients with a glomerular filtration rate (eGFR) of 35 ml/min/1.73m2 or less between 2006 and 2016. Median age was 58(51-74) years. Five patients were on haemodialysis at diagnosis and 4 went into ASCT while on haemodialysis. Six patients had light chain multiple myeloma. Initial therapy was bortezomib based in 6 patients, with 4 receiving thalidomide and 1 received both thalidomide and bortezomib pre ASCT. Most patients were mobilised with G-CSF alone and only 1 received cyclophosphamide and G-CSF. ASCT was conditioned in all cases with 140mg/m2of Melphalan. Patients on hemofiltration were supported during ASCT as per institutional guidelines. We collected data on response, stem cell collection, engraftment, progression free survival (PFS), overall survival (OS) and treatment related mortality (TRM). Results: Median follow up for the whole group was 24 (6-114) months. Pre ASCT 6 patients were in VGPR and 3 in PR. The median cell dose collected was 6.92×10 6 CD34 cells/kg (range 3.06-8.27). The median time to neutrophil engraftment (absolute neutrophil count>0.5×109/L) and platelet engraftment (>20×109/L) was at day 13 and 15 respectively. The TRM at day+100 was 0%. Post ASCT best responses were as follows-7 patients were in VGPR; 1 in PR and 1 progressed. The median PFS was 24months and median OS was 27 months. At the time of data collection only one person had died. The cause of death was disease progression with refractory disease. One patient became free of haemodialysis pre ASCT, one after ASCT and 1 more dropped frequency of dialysis sessions from 3 to 2 per week. Discussion: Autologous stem cell transplant using low dose Melphalan (140mg/m2) as consolidation post a bortezomib based induction therapy is an effective and safe treatment option for the pre-dialysis and dialysis patients with multiple myeloma. In our hands the TRM is extremely low suggesting the lower dose to be more appropriate than melphalan at 200mg/m2. It provides good PFS and in some cases freedom from haemodialysis. Further prospective trials are needed to confirm these findings. Disclosures Paneesha: Abvie: Honoraria. Kishore:celgene: Other: travel grant.

Sign in / Sign up

Export Citation Format

Share Document